Clinical trial · Interventional
Pedometer Activity Monitoring After ASCT
Clinical Trial Investigating Pedometer-based Activity Monitoring After Autologous Transplantation in Lymphoma and Myeloma Patients
NCT03238599CI-TRIAL-00065232PAMALcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The trial assess the proportion of patients who resumed their professional activity within 100 days after ASCT (autologous stem cell Transplantation).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Autologous Stem Cell Transplantation | — | UNRESOLVED | — |
| High-dose Chemotherapy | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pedometer-based activity monitoring after ASCT | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pedometer-based activity monitoring
- description
- The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
- interventionNames
- Behavioral: Pedometer-based activity monitoring after ASCT
Primary outcomes (1)
- measure
- Professional Activity
- timeFrame
- 100 days
- description
- Number of patients who resumed their professional activity within 100 days after ASCT.
Secondary outcomes (3)
- measure
- Physical activity
- timeFrame
- 100 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with plasma cell disorders (myeloma and amyloidosis) or with lymphomas (NHL and Hodgkin) undergoing high-dose chemotherapy with autologous stem cell transplantation. * Patients must be aged 18-65 years. * Patients must have given voluntary written informed consent. * Patients without professional activity (such as due to early retirement, dependency on disability reimbursement, or unemployment) are eligible. Exclusion Criteria: * Patients with other serious medical condition that could potentially interfere with the completion of treatment according to this protocol. * Lack of patient cooperation to allow study treatment as outlined in this protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.